<DOC>
	<DOCNO>NCT01694394</DOCNO>
	<brief_summary>The primary objective study determine rate detection sub-clinical atrial fibrillation ( ≥ 5 minute ) within average 12 month follow implant St. Jude Medical Confirm ( R ) Implantable Cardiac Monitor patient know cardiovascular risk factor leave atrial enlargement , without prior AF .</brief_summary>
	<brief_title>Prevalence Sub-Clinical Atrial Fibrillation Using Implantable Cardiac Monitor</brief_title>
	<detailed_description>Title Study Prevalence Sub-Clinical Atrial Fibrillation Using Implantable Cardiac Monitor Patients Cardiovascular Risk Factors ( ASSERT-II ) Short Title ASSERT-II Study Sponsor Population Health Research Institute ( Grant Aid St. Jude Medical , Inc. ) Principal Investigators Dr. J. Healey , Dr. S. Connolly , Dr. M. Alings Central Coordinating Centre Population Health Research Institute Recruitment Participating Clinical Sites 250 patient approximately 30 Sites Phase/Regulatory Status Phase IV - Cohort Study Hypothesis Among elderly patient cardiovascular risk factor leave atrial diameter ≥ 4.4 cm , without prior clinical AF , implant continuous ECG monitor ( St. Jude Medical Confirm® Implantable Cardiac Monitor ) detect subclinical AF ( ≥ 5 minute duration ) 12 % patient average follow-up 12 month . Study Objectives Primary Objectives : 1 . To determine rate detection sub-clinical atrial AF ( ≥ 5 minute ) within average 12 month follow implant St. Jude Medical Confirm® Implantable Cardiac Monitor patient know cardiovascular risk factor leave atrial enlargement , without prior AF . Secondary Objectives 1 . To determine incidence sub-clinical AF high among patient whose left atrial volume median value observe study . 2 . To determine relationship left atrial volume ( continuous variable ) risk sub-clinical AF . 3 . To evaluate potential predictor sub-acute AF population include : baseline troponin-T , baseline NT-pro-BNP well clinical echocardiographic parameter . 4 . To develop preliminary economic analysis evaluate potential cost-effectiveness screening patient population Implantable Cardiac Monitor mean prevent stroke . Study Design Cohort study determine prevalence sub-clinical AF elderly population common cardiovascular risk factor , hypertension diabetes . Patients echocardiographic evidence atrial enlargement enrol St. Jude Medical Confirm® Implantable Cardiac Monitor ( Confirm® ICM ) subcutaneously implant . To reduce cost , case implant do conjunction plan surgery heart catheterization . PHRI : CONFIDENTIAL Final Version 2.0:2012-06-18 Page 4 24 Participants/Study Duration Total 250 participant enrol 16 month . The last patient enrol 9 month follow-up , total study duration approximately 25 month . Clinic visit occur enrolment month 3 , 6 9 . A final visit take place 18 month follow-up , last patient enrol follow 9 month ( whichever come first ) . Study Population Patients know cardiovascular risk factor leave atrial enlargement , prior document AF . Intervention St. Jude Medical Confirm® Implantable Cardiac Monitor ( Confirm® ICM ) Enrollment Follow-up Eligible consent patient enrol Confirm® ICM implant . The implant may take place conjunction pre-planned non-cardiac surgery , heart catheterization , stand-alone procedure . Follow-up visit occur month 3 , 6 9 . A final visit take place 18 month follow-up , last patient enrol follow 9 month ( whichever come first ) . Assessment Outcome Events An independent central adjudication committee comprise arrhythmia expert evaluate device-detected AF episode . Statistical Methodology Determine incidence sub-clinical atrial AF ( ≥ 5 minute ) use Confirm® ICM . Date Protocol June 18 , 2012</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Inclusion Criteria Patients eligible inclusion meet follow : 1 . Age ≥ 65 , plus : CHA2DS2VASc score ≥ 2 Or Obstructive sleep apnea ( documented polysomnography , ambulatory oximetry , positive Berlin Questionnaire require use CPAP/BiPAP ) Or BMI &gt; 30 2 . Echocardiographic biochemical evidence increase risk AF : Left atrial enlargement clinical echocardiography time prior enrollment ( defined LA volume ≥ 58 ml LA diameter ≥ 4.4 cm ) Or Serum NTProBNP ≥ 290 pg/mL Exclusion Criteria 1 . Previously document history atrial fibrillation atrial flutter 2 . Current chronic treatment oral anticoagulation ( i.e . perioperative prophylaxis would eligible ) 3 . Patient implant pacemaker defibrillator atrial lead 4 . Definitive plan cardiac surgery next 6 month ( patient coronary angiography possibility cardiac surgery still eligible )</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>implantable cardiac monitor</keyword>
	<keyword>leave atrial enlargement</keyword>
	<keyword>CHA2DS2 VASc Score</keyword>
	<keyword>cardiovascular risk</keyword>
</DOC>